| Literature DB >> 29260298 |
Oluyomi Stephen Adeyemi1,2, Tatsuki Sugi1, Yongmei Han1, Kentaro Kato3.
Abstract
Toxoplasma gondii is the etiological agent of toxoplasmosis, a common parasitic disease that affects nearly one-third of the human population. The primary infection can be asymptomatic in healthy individuals but may prove fatal in immunocompromised individuals. Available treatment options for toxoplasmosis patients are limited, underscoring the urgent need to identify and develop new therapies. Non-biased screening of libraries of chemical compounds including the repurposing of well-characterized compounds is emerging as viable approach to achieving this goal. In the present investigation, we screened libraries of natural product and FDA-approved compounds to identify those that inhibited T. gondii growth. We identified 32 new compounds that potently inhibit T. gondii growth. Our findings are new and promising, and further strengthen the prospects of drug repurposing as well as the screening of a wide range of chemical compounds as a viable source of alternative anti-parasitic therapeutic agents.Entities:
Keywords: Anti-parasitic; Drug discovery; FDA-approved compounds; Natural products; Toxoplasmosis
Mesh:
Substances:
Year: 2017 PMID: 29260298 DOI: 10.1007/s00436-017-5698-1
Source DB: PubMed Journal: Parasitol Res ISSN: 0932-0113 Impact factor: 2.289